Cellestia Company
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers.
Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
.png)
Employee Number:
11-50
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Founded Date:
2014-01-01
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Investors:
EISMEA, Foundation for Innovation and Technology (FIT), GoBeyond, Innosuisse, Partners Investment
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland
Founders:
Dirk Weber, Rajwinder Lehal